Oral Bisphosphonates: Ongoing Safety Review of Atypical Subtrochanteric Femur Fractures

FDA review of available data have not shown a clear connection between bisphosphonate use and a risk of atypical subtrochanteric femur fractures.

Related Posts:

1. Benicar (olmesartan): Ongoing Safety Review
2. Stalevo (entacapone/carbidopa/levodopa): Ongoing Safety Review
3. Avandia (rosiglitazone): Ongoing Review of Cardiovascular Safety
4. Proton Pump Inhibitors (PPI): Class Labeling Change
5. Lasko Recalls Portable Electric Heaters Due To Fire Hazard